Nut Midline Carcinoma — Clinical Trials

MONDO:00055637 active·5 recruitingLast updated: Mar 16, 2026, 6:52 AM

Trial Landscape

Nut Midline Carcinoma has a growing clinical research program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment2

Procedure2

Gene Therapy1

Biological Therapy1

4 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

4 trials are observational or have no phase designation.

Sponsor Types

Academic/Other4Industry2NIH1

Top Sponsors

Epigenetix, Inc.

TScan Therapeutics, Inc.

Trial Locations

United States5 trials

China1 trial

Italy1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

3 of 7 Trials

Phase 2Recruiting

NCT07050186

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

Sponsor:Northwestern University

United StatesStarted: Aug 2025Est. completion: Nov 2035Updated: Sep 2025

Phase 1Recruiting

NCT05019716

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2022Est. completion: Jun 2026Updated: Mar 2026

Phase 1Recruiting

NCT05488548

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Sponsor:Epigenetix, Inc.

United StatesStarted: Dec 2022Est. completion: May 2025Updated: Jan 2025

Stay informed about clinical trials for Nut Midline Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 6:52 AM